Summary
Amgen Inc. has announced a significant leadership transition with the upcoming retirement of Executive Vice President and Chief Technology Officer, David M. Reese, effective June 30, 2026. This departure marks the end of an era for Dr. Reese's tenure, during which he held a critical role in shaping the company's technological direction. In response to Dr. Reese's retirement, Amgen is redistributing the responsibilities of the CTO role to a triumvirate of executive leaders: James E. Bradner (EVP, Research and Development, Artificial Intelligence and Data), Murdo Gordon (EVP, Amgen Global Markets and Policy), and Peter H. Griffith (EVP and Chief Financial Officer). This strategic reallocation, effective June 1, 2026, aims to further integrate science, technology, and data across the organization, fostering stronger alignment between commercial, medical, and policy functions. Dr. Reese will continue to serve in an advisory capacity until his retirement.
Key Highlights
- 1David M. Reese, EVP and Chief Technology Officer, is retiring effective June 30, 2026.
- 2Dr. Reese's responsibilities will be redistributed among three key executives: James E. Bradner, Murdo Gordon, and Peter H. Griffith.
- 3The redistribution of duties is designed to enhance the integration of science, technology, and data within Amgen.
- 4The move aims to build stronger alignment between commercial, medical, and policy teams.
- 5The changes in responsibility distribution will take effect on June 1, 2026, prior to Dr. Reese's final departure.
- 6Dr. Reese will remain employed until his retirement date and will receive retirement benefits as per company policy.
- 7A press release announcing the transition has been furnished as part of the filing.